Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.68 (tissue plasminogen activator)
 11,311 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The synthetic analog of vasopressin desmopressin (DDAVP) is widely used for the treatment of patients with von Willebrand disease (VWD), hemophilia A, several platelet disorders, and uremic bleeding. DDAVP induces an increase in plasma levels of von Willebrand factor (VWF), coagulation factor VIII (FVIII), and tissue plasminogen activator (t-PA). It also has a vasodilatory action. In spite of its extensive clinical use, its cellular mechanism of action remains incompletely understood. Its effect on VWF and t-PA as well as its vasodilatory effect are likely explained by a direct action on the endothelium, via activation of endothelial vasopressin V2R receptor and cAMP-mediated signaling. This leads to exocytosis from Weibel Palade bodies where both VWF and t-PA are stored, as well as to nitric oxide (NO) production via activation of endothelial NO synthase. The mechanism of action of DDAVP on FVIII plasma levels remains to be elucidated. The hemostatic effect of DDAVP likely involves additional cellular effects that remain to be discovered.
 ...
PMID:Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). 1287 1

Desmopressin (DDAVP) is a well tolerated and convenient haemostatic agent that can be used in a number of clinical conditions with bleeding diathesis. It has several effects on the haemostatic system, causing endogenous release of coagulation factor VIII, von Willebrand factor and tissue-type plasminogen activator, among others. In this review we present a growing body of evidence showing that DDAVP treatment may impair spread of cancer cells and contribute to encapsulation of tumour tissue. Our data in preclinical animal models suggest a potential application of DDAVP in the perioperative management of aggressive solid tumours. Novel vasopressin analogues with improved antitumor effects are currently in development.
 ...
PMID:Desmopressin and other synthetic vasopressin analogues in cancer treatment. 1651 12

A radioimmunoassay (RIA) has been set up using purified human melanoma tissue plasminogen activator and a specific antiserum raised against it. Concentration of antigen in citrated plasma of resting human subjects was found to be 7.1 +/- 1.6 ng/ml (mean +/- S.D.) while the lower limit of sensitivity of the RIA was 2 ng/ml. After venous occlusion or DDAVP infusion the levels of antigen were invariably elevated and a significant increase in the proportion of antigen having fibrin binding properties was observed. Decay studies in vitro and gel filtration of post-stimulus plasma indicated that the RIA detects active and inactive forms of antigen and the possible nature of the inactive antigen is discussed.
 ...
PMID:Tissue plasminogen activator in human plasma measured by radioimmunoassay. 2021 2


<< Previous 1 2 3 4 5